Medicinal cannabis extracts for the treatment of multiple sclerosis

Current Opinion in Investigational Drugs

Volumn 5, Issue 7, 2004, Pages 727-730

  Smith, Paul F ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoids; Cannabis; Multiple sclerosis; Pain; Spasticity

Indexed keywords

CANNABIS; PLANT EXTRACT; TETRAHYDROCANNABINOL;

ANIMAL; ARTICLE; CHEMISTRY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVALUATION; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MULTIPLE SCLEROSIS; PAIN; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SPASTICITY;

ANIMALS; CANNABIS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PAIN; PHYTOTHERAPY; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS; TETRAHYDROCANNABINOL;

EID: 5044247112     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Iversen L: Cannabis and the brain. Brain (2003) 126(6):1252-1270.
2. Walker JM, Huang SM: Cannabinoid analgesia. Pharmacol Ther (2002) 95(2):127-135.
3. Rice AS: Cannabinoids and pain. Curr Opin Invest Drugs (2001) 2(3):399-414.
4. Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol (2001) 63(5):569-611.
5. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature (1998) 394(6690):277-281.
6. Elphick MR, Egertova M: The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond (2001) 356(1407):381-408.
7. Kreitzer AC, Regehr WG: Retrograde signaling by endocannabinoids. Curr Opin Neurobiol (2002) 12(3):324-330.
8. Alger BE: Retrograde signaling in the regulation of synaptic transmission: Focus on endocannabinoids. Prog Neurobiol (2002) 68(4):247-286.
9. 1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse (2001) 41(3):195-202.
10. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2001) 15(2):300-302.
11. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404(6773):84-87.
12. British Medical Association: Therapeutic uses of Cannabis. Harwood Academic Publishers, Amsterdam, the Netherlands (1997).
13. Hall WD, Degenhardt LJ, Currow D: Allowing the medical use of cannabis. Med J Aust (2001) 175(1):39-40.
14. Consroe P, Musty R, Rein J, Tillery W, Pertwee R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol (1997) 38(1):44-48.
15. Smith PF: Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Invest Drugs (2002) 3(6):859-864.
16. Smith PF: Cannabinoids for the treatment of multiple sclerosis: No smoke without fire? Expert Rev Neurotherapeutics (2003) 3:327-357.
17. Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH: Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology (2002) 58(9):1404-1407.
18. Dyer O: Cannabis trial launched in patients with MS. Br Med J (2001) 322:192.
19. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre, randomised placebo-controlled trial. Lancet (2003) 362(9395):1517-1526.
20. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Heinzel M, Schnelle M: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis. Symposium on the Cannabinoids, Pacific Grove, CA, USA (2003):57.
21. Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil (2003) 17(1):21-29.
22. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J: The effects of cannabis on tremor in patients with multiple sclerosis. Neurology (2004) 62(7):1105-1109.
23. GW Pharmaceuticals plc: GW Announces Positive Results From Each of Four Phase Three Clinical Trials. Press Release (2002) November 11. http://www.gwpharm.com/news-press-releases.asp?id=/gwp/pressreleases/ currentpress/2002-11-05/
24. GW-1000 (GW Pharmaceuticals Ltd). Investigational Drugs Database (June 2004).
25. Cannabis-based medicines - GW Pharmaceuticals: High CBD, high THC, medicinal cannabis - GW Pharmaceuticals, THC:CBD. Drugs R&D (2003) 4(5):306-309. http://www.idmu.co.uk/gwjun2003.htm
26. Smith PF: GW-1000, GW Pharmaceuticals. Curr Opin Invest Drugs (2004) 5(7):748-754.
27. Mechoulam R, Hanus L: Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids (2002) 121(1-2):35-43.
28. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, Martin BR, Bukoski RD, Kunos G: Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 63(3):699-705.
29. 9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci (1998) 63(1):PL1-6.
30. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V: Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmaccol (2001) 134(4):845-852.
31. Mechoulam R, Parker LA, Gallily R: Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol (2002) 42(Suppl 11):11S-19S.
32. Pertwee RG, Ross RA, Craib SJ, Thomas A: (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol (2002) 456(1-3):99-106.
33. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M: The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collageninduced arthritis. Proc Natl Acad Sci USA (2000) 97(17):9561-9566.
34. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J (2001) 323(7303):13-16.
35. Tramer MR, Caroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ: Cannabinoids for control of chemotherapy-induced nausea and vomiting: Quantitative systematic review. Br Med J (2001) 323(7303):16- 21.
36. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. J Am Med Assoc (2003) 290(13):1757-1762.
37. O'Connor P: Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology (2002) 59(6 Suppl 3):S1-S33.
38. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE: Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. Br Med J (2002) 325(7374):1212-1213.
39. Fergusson DM, Horwood LJ, Swain-Campbell NR: Cannabis dependence and psychotic symptoms in young people. Psychol Med (2003) 33(1):15-21.
40. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW: Abstinence symptoms following oral THC administration to humans. Psychopharmacology (1999) 141(4):385-394.
41. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW: Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (1999) 141(4):395-404.
42. Tanda G, Pontieri FE, Di Chiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science (1997) 276(5321):2048-2050.
43. Tanda G, Munzar P, Goldberg SR: Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci (2000) 3(11):1073-1074